Mercados españoles abiertos en 5 hrs 17 min

Endo International plc (ENDP)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
0,4650-0,1128 (-19,52%)
Al cierre: 04:00PM EDT
0,4800 +0,01 (+3,23%)
Después del cierre: 07:59PM EDT
Inicia sesión para publicar un mensaje.
  • E
    EricInPDX
    $ENDP conversation
    TOO FUNNY!!

    Jedd
    5 years ago
    $ENDP conversation
    Just bought 1200 ENDP at $13.82. Way oversold/undervalued. Target $17 ST.
  • B
    Bill
    $GME conversation
    EricInPDX
    2 days ago
    Replied to a reaction
    $ENDP conversation
    what other handles does mike/Jedd use these days? Is he still on FIVE masquerading as someone?

    He's pretty much stopped posting with his five handles on CIEN too ==> (YourDoseOfReality,syd,clyde,DrHotStock).

    He still likes to post with "fake EricInPDX" when he gets really upset and posts on GME. I was short and covered today,
  • p
    paul
    EricInPDX
    2 days ago
    Replied to a reaction
    $ENDP conversation
    what other handles does mike/Jedd use these days? Is he still on FIVE masquerading as someone?

    He's pretty much stopped posting with his five handles on CIEN too ==> (YourDoseOfReality,syd,clyde,DrHotStock).

    He still likes to post with "fake EricInPDX" when he gets really upset and posts on GME. I was short and covered today,
  • s
    scott
    $FIVE conversation
    #ENDP Oh forgot to mention ENDP is GOING TO $10 just like I said. We are just waiting on the first major catalyst - a GS. Then the (better than predicted) uptake of premixed Vaso viles and maintenance of market share/volume and margins and ultimately much stronger EBITDA than guided. Coleman just like his mentor Campanelli always play it super it conservative. Draw the shorts in and then destroy them. Just like I predicted FIVE's demise and the soon to be felt effects of higher rates ENDP will be $10.

    Haha I WIN!
  • l
    lorenzo s
    $TEVA conversation
    I am copying from $endp conversation

    Great Barron's article on the opioid lawsuit. Note how the author was expecting a $50B award in California and that is essentially zero after the debacle in Orange County.

    Also note how the author states that this will precipitate a settlement because it is in the best interest of both parties.

    I think that both sides settle nationwide with proposed amount
    Teva to pay $500 million and about 23 billion in medicines for addiction over a 10 year period

    -----------------------------------------

    After a yearlong delay caused by the pandemic, a New York jury is set to hear a case later this month that could finally bring progress in the sprawling government litigation seeking to hold corporations liable for the opioid crisis.

    New York state and two of its counties, Nassau and Suffolk on Long Island, are suing a number of companies, including Johnson & Johnson (ticker: JNJ), McKesson (MCK) and Teva Pharmaceutical Industries (TEVA), for monetary damages. Jury selection is set to begin Tuesday.

    The trial, along with three others in the country, ends the long pause in efforts by states, counties and local governments to recover funds spent combating the epidemic, especially the costs associated with prevention and treatment.

    In a note on Friday, RBC Capital Markets analyst Daniel Busby said the renewed litigation could end the drawn-out legal battle. The New York case will be the biggest, most complicated trial so far, and the first heard in front of a jury, he noted.

    “The start of the New York opioid trial later this month is emblematic of a broader pick-up in opioid litigation activity across the US,” Busby wrote. “Collectively, we believe these trials could increase the impetus for a global settlement, or at the very least, better inform manufacturer liability estimates as trial decisions are rendered in ~2H2021 and beyond.”

    Nearly 500,000 people died of opioid overdoses between 1999 and 2019, according to the Centers for Disease Control and Prevention—and the crisis shows no signs of slowing. The 12 months ending in May 2020 saw more than 81,000 drug overdose deaths, the most ever recorded in a year, the CDC reported.

    For years, state and local governments have brought court challenges against companies in the opioid supply chain, including Johnson & Johnson, Teva Pharmaceutical Industries, Endo International (ENDP), Cardinal Health (CAH), AmerisourceBergen (ABC), and CVS Health (CVS), and others. Purdue Pharma, the private company that makes OxyContin, which many government lawsuits have said fueled the epidemic, filed for bankruptcy because of the litigation.

    The litigation is extraordinarily complex, and involves thousands of plaintiffs and a large number of defendants. The companies generally argue that they were selling, manufacturing, or distributing legal products, and aren’t responsible for abuse.

    While some state attorneys general have signed a tentative agreement with some of the defendants, the deal hasn’t been completed. The last major opioid trial ended in 2019, and the CEO of one pharmaceutical company attributed the slowdown in settlement negotiations to the pandemic and the delay of the New York trial.

    “Not much has happened,” Teva CEO Kåre Schultz told Barron’s in August, when asked about progress toward a settlement. “We haven’t really been pushed to a final conclusion.”

    The litigation payouts could ultimately be in the tens of billions of dollars, spread across a number of public companies. They have acted as an overhang on a number of stocks for years. RBC’s Busby wrote that he expects a total opioid liability for drug manufacturers alone of $57 billion.

    The amount of damages being sought in a California case, one of the four highlighted by Busby, is $50 billion. That trial started in April and is still going on, as is one in West Virginia that started in May. The fourth, in Tennessee, is scheduled to being in July.

    Sectors impacted by the litigation have trailed the market over the past year. The S&P 500 Health Care Distributors index is up 16.6% over the past 12 months, while the broader S&P 500 is up 34.3%. Teva is down 17.7% over the same period, while Endo is up 35.5%.
  • S
    Sergey
    $ENDP conversation
    $ENDP settlements update:
    Dec 23, 2022 - Texas 🤝 $63 m
    Nov 2, 2022 - California ✅ WIN
    Sep 28, 2022 - Louisiana 🤝 $7.5 m
    Sep 9, 2022 - New York 🤝 $50 m
    July 22, 2022 - Tennessee 🤝 $35 m
    Jan 10, 2020 - Oklahoma 🤝 $8.75 m
    Aug 20, 2019 - Ohio 🤝 $11 m

    While Cali is #1 state population wise, TX is #2, NY #4, Ohio #7.

    Thoughts:
    - opioid lawsuits are soon to be settled, look at the dynamics: 5 deals announced in ‘21 vs. just one in ‘20,
    - GS is the most likely option, I bet for Jan-Mar timeline, as Endo already took care of the biggest states,
    - if not - that’s okay too, we’re on the right track.

    Buying more and going into vacation in style🚀
  • C
    Chad
    $GME conversation
    EricInPDX55 minutes agoReplied to a reaction
    $ENDP conversation
    btw ... I'm long GME PUTs right now.
  • F
    Foxxy
    $ENDP conversation
    Endo Int'l $ENDP CEO To Announce Major New York Based Institutional Fund To Make Significant Investment In Company
  • F
    Foxxy
    $ENDP conversation
    Endo Int'l $ENDP To be Featured on CNBC "Squawk Box" Segment, Share Price To Rise On Nationwide Exposure

    https://mobile.twitter.com/RumorMurmurBuzz/status/1300191049743101953
    Twitter
    mobile.twitter.com
  • J
    Jeff
    $ENDP conversation
    I'm guessing $ENDP and $TEVA are both down because yesterday a bankruptcy judge declined to pause litigation in the JNJ talc cases in which it is attempting to move the assets to a separate company that is going to file Chapter 11 to force a settlement. This tactic is being watched closely by all involved in Opioid litigation as it offers more pressure for settlement if it works for JNJ.
  • t
    time
    $GME conversation
    Note onl;y can I lose over $40K in GME, I also lost over $20K in ENDP!
    ===
    Jedd
    4 years ago
    $ENDP conversation
    Gabelli & Co reiterates Buy, $29 target. (11/9/2016:)
    "We recognize the significant challenges facing ENDO's businesses, but we also believe that the current valuation more than reflects this reality. We continue to view specialty and generic pharma as good businesses worth 10-12X EBITDA over the long term. Completions of the business review and potential divestitures coud serve as catalysts for 2017."
  • A
    Anonymous
    $MNK conversation
    Sitting on 52,000 shares of $MNK and 20000 shares of $ENDP. I am up about 30% on my overall position (I started accumulating a position when both touched low $3s), but the volatility of these stocks in nauseating. Friday morning I go into a meeting and MNK is at $5.15, walk back out of the meeting and the stock was at $4.70.

    I'm in it for the long hall, as I have written out of money covered calls, with most expiring in Jan 21 or Jan 22. If MNK can get to $7, I can legitimately start thinking of retiring early. If it crashes... well, I probably will need a new job and a new wife.

    Fingers crossed

    P.S: For those who don't mind forfeiting potential upside, covered call premiums are super juicy right now.
  • A
    Anonymous
    $NVAX conversation
    Capitulation?

    Bio-tech taking it on the chin again. $XBI broke $100 - can't believe that this was $236.50 on December 20th.

    Losing my shirt on $ENDP and $VXRT too.
  • S
    Sean
    $ENDP conversation
    @CitronResearch 11h (10/17/19)
    Mkt realizing that $ENDP is the real beneficiary of opioid settlement as reported. Fundamentals have improved since stock was at $18 a year ago. Low or no cash payout. Good FCF, balance sheet, and strong pipeline. If reporting is true $ENDP can be $10 on Mon.
  • F
    Fissber
    $ENDP conversation
    #ENDP P/E stands at 1.61, which indicates that it is highly undervalued. Technical looks strong according to stoxline. On watch for clear above 6.38.
  • E
    EricInPDX
    $GME conversation
    Jedd's past record, as evidenced below speaks for itself! Longs pile in …. how can someone pumping GME from $26 (down 80%) for over three years and chasing shorts on the ENDP message board (now $4, down 80% since he pumped) be wrong? "Jedd" (not his real name) has definitely been around the block. Hope this helps ….
    ====
    Jedd 3 years ago
    $GME conversation
    Gamestop free cash flow for 2016 roughly $400 million. This is after interest payments, taxes, and capex. The current dividend is about $150 million annually. Its not only safe, but leaves room for stock buybacks. Stock is trading at 6 times earnings and yielding 6%. The latest noise regarding MSFT subscription offering is nothing new for GME. Seems their offering lacks games from Electronic Arts and Activision anyway. back to $28 after earnings imho.
    ===
    Jedd 2 years ago
    $GME conversation
    Added 1000 at $12.53. can't help myself. The cash flow numbers have to matter eventually.
    ====
    Jedd 3 years ago
    $ENDP conversation
    Hey Joey,
    Are we at "$10" yet clown?
    Well you do still have 2 days left but it won't matter. Just like your opinion on what will transpire in 2017 for ENDP doesn't matter. Leave the forecasting for folks who have been around the block at least once.
    ===
    Jedd 3 years ago
    $ENDP conversation
    Just bought 1200 ENDP at $13.82. Way oversold/undervalued. Target $17 ST.
    ===
  • E
    EricInPDX
    $GME conversation
    With the continued weakness of Game Stop, it may be time to have a good chuckle on Jedd's first two posts on the GME message board over two years ago. For more laughs, click on his handle, sort by oldest posts and read all his posts about $ENDP. They are equally as comical. It is important to note though that Jedd has made bank on GME the past three years ….
    ===
    Jedd
    2 years ago
    $GME conversation
    Gamestop free cash flow for 2016 roughly $400 million. This is after interest payments, taxes, and capex. The current dividend is about $150 million annually. Its not only safe, but leaves room for stock buybacks. Stock is trading at 6 times earnings and yielding 6%. The latest noise regarding MSFT subscription offering is nothing new for GME. Seems their offering lacks games from Electronic Arts and Activision anyway. back to $28 after earnings imho.

    Jedd 2 years ago
    Replied to a reaction
    $GME conversation
    Its apparent that you really do not understand GME or the basic principles of valuation and cash flow. GME's rising margins and ability to absorb declining physical game sales has everything to do with managements move into Technology stores. As for you stating its down from $57-- that's meaningless for me. My cost is $23.90. I'm taking your money kid.
  • J
    Jeff
    $ENDP conversation
    opioid settlements put $endp back in play for more institutional investors by taking out a ton of risk. Purdue settlement is great news. It will be interesting to see how the payment is structured.
  • R
    Rich
    $ENDP conversation
    Once you start to see this on ST time to run away— so many MNK similarities anymore it’s hard to ignore.:

    $ENDP
    starting to accumulate here for long term position. It's just screaming value. Price is too low to ignore any longer.
  • S
    Sunwab
    $ENDP conversation
    #ENDP has P/E of 2.84, highly undervalued. Bullish indication in MACD and RSI. http://www.foxchart.com/share/142227765.png